Current report No. 2/2023
Date prepared: 06/02/2023
Abbreviated name of the issuer: CELON PHARMA S.A.
Subject: Receipt of a notification regarding a change in the total number of votes in the Company
Legal basis: Article 70 point 1 of the Act on Public Offering – acquisition or disposal of a significant block of shares
Content of the report:
The Management Board of Celon Pharma S.A. (“Company”) hereby informs of receiving a notification dated February 2023 from Generali Powszechne Towarzystwo Emerytalne S.A. („Generali PTE”) on the funds managed by Generali PTE exceeding the 5% threshold in the total number of votes in Celon Pharma S.A. as a result of Generali PTE’s management acquisition of NNLife Otwarty Fundusz Emerytalny and NNLife Dobrowolny Fundusz Emerytalny on February 1, 2023.
After the management acquisition, the funds managed by Generali PTE in total held 4,083,585 of the Company’s shares, which constituted an 8.00% share in its share capital and gave the right to exercise 4,083,585 votes at its general meeting, i.e. to 6.18% of the total number of votes in the Company.
The full contents of the notification constitute an appendix to this report.